Biologic Therapies for Uncontrolled Asthma: Comparative Review Findings
Key Takeaways
- Indirect comparisons in severe uncontrolled asthma linked dupilumab and tezepelumab with more favorable annualized exacerbation outcomes than several comparator biologics.
- In eosinophilic asthma, mepolizumab, tezepelumab, and dupilumab showed more favorable signals across eosinophil-defined subgroups.
- One indirect comparison suggested lower odds of serious adverse events with mepolizumab, while biologics were described as potentially effective and generally safe despite critically low review quality.
Researchers conducted an overview of systematic reviews that included meta-analyses or network meta-analyses on biologic therapies for uncontrolled asthma. The included agents were omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab across the synthesized literature. Searches spanned Medline/PubMed, Embase, LILACS, Web of Science, and the Cochrane Library, with MeSH and Emtree terms organized according to PICOT. Because the synthesis linked results across reviews and networks, the contrasts reflected indirect comparative evidence rather than direct testing.
In eosinophilic asthma, mepolizumab, tezepelumab, and dupilumab were more favorable across eosinophil-defined subgroups. Those subgroup thresholds were at least 400 cells/μL, at least 300 cells/μL, at least 150 cells/μL, and less than 150 cells/μL. These thresholds covered several biomarker-defined populations rather than a single eosinophil cutoff.
In corticosteroid-dependent asthma, selected indirect comparisons also favored benralizumab and dupilumab on reported outcomes. The strongest comparative distinctions remained tied to phenotype and population context throughout the synthesis.
In severe uncontrolled asthma, dupilumab and tezepelumab were associated with more favorable annualized exacerbation rate outcomes than benralizumab, mepolizumab, and reslizumab.
Other endpoint-specific differences emerged across lung function, symptom control, and quality-of-life measures within the indirect evidence base. Selected comparisons favored dupilumab for FEV1, pointing to a more favorable lung function signal in that setting. Mepolizumab was associated with more favorable ACQ results in several specific comparisons. Quality-of-life signals differed by population, with omalizumab favored for AQLQ in the general population. Tezepelumab was favored for AQLQ in eosinophilic asthma, showing that outcome patterns varied by endpoint and phenotype.
Safety reporting was limited, but one indirect comparison suggested lower odds of serious adverse events with mepolizumab. The authors concluded that biologic therapies may be effective and generally safe options for uncontrolled asthma. That overall conclusion remained qualified by the review base rather than a broad set of direct comparative safety trials. Most included reviews were judged critically low in methodological quality, which narrowed confidence in the pooled comparative picture. The authors said more standardized, methodologically rigorous future studies are needed to strengthen this evidence base.